These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11742595)

  • 1. Is tolterodine (Detrol) or oxybutynin (Ditropan) the best for treatment of urge urinary incontinence?
    Blonski J
    J Fam Pract; 2001 Dec; 50(12):1017. PubMed ID: 11742595
    [No Abstract]   [Full Text] [Related]  

  • 2. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.
    Appell RA; Sand P; Dmochowski R; Anderson R; Zinner N; Lama D; Roach M; Miklos J; Saltzstein D; Boone T; Staskin DR; Albrecht D;
    Mayo Clin Proc; 2001 Apr; 76(4):358-63. PubMed ID: 11322350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is extended-release oxybutynin (Ditropan XL) or tolterodine (Detrol) more effective in the treatment of an overactive bladder?
    Hartnett NM; Saver BG
    J Fam Pract; 2001 Jul; 50(7):571. PubMed ID: 11485700
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
    Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
    Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
    Wein AJ
    J Urol; 2005 Jun; 173(6):2056-7. PubMed ID: 15879827
    [No Abstract]   [Full Text] [Related]  

  • 6. A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women.
    Sand PK; Miklos J; Ritter H; Appell R
    Int Urogynecol J Pelvic Floor Dysfunct; 2004; 15(4):243-8. PubMed ID: 15517668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence.
    Davila GW; Daugherty CA; Sanders SW;
    J Urol; 2001 Jul; 166(1):140-5. PubMed ID: 11435842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence.
    Dmochowski RR; Sand PK; Zinner NR; Gittelman MC; Davila GW; Sanders SW;
    Urology; 2003 Aug; 62(2):237-42. PubMed ID: 12893326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial.
    Chu FM; Dmochowski RR; Lama DJ; Anderson RU; Sand PK
    Am J Obstet Gynecol; 2005 Jun; 192(6):1849-54; discussion 1854-5. PubMed ID: 15970828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice.
    Oki T; Maruyama S; Takagi Y; Yamamura HI; Yamada S
    Eur J Pharmacol; 2006 Jan; 529(1-3):157-63. PubMed ID: 16316647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. POEMS (patient-oriented evidence that matters) spark discussion.
    Weiss BD
    J Fam Pract; 2001 Oct; 50(10):901. PubMed ID: 11674898
    [No Abstract]   [Full Text] [Related]  

  • 12. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials.
    Nijman RJ; Borgstein NG; Ellsworth P; Djurhuus JC
    J Urol; 2005 Apr; 173(4):1334-9. PubMed ID: 15758796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder.
    Arikian SR; Casciano J; Doyle JJ; Tarride JE; Casciano RN
    Manag Care Interface; 2000 Feb; 13(2):88-94. PubMed ID: 11067391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do anticholinergics affect reaction time? A possible impact on the course of rehabilitation.
    Karataş GK; Günendi Z
    NeuroRehabilitation; 2010; 27(2):141-5. PubMed ID: 20871143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in medical management of overactive bladder.
    Richelson E; Elliott DS
    Mayo Clin Proc; 2003 Jun; 78(6):681-3. PubMed ID: 12934775
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxybutynin transdermal (Oxytrol) for overactive bladder.
    Med Lett Drugs Ther; 2003 May; 45(1156):38-9. PubMed ID: 12736598
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin.
    Perfetto EM; Subedi P; Jumadilova Z
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S150-7. PubMed ID: 16161388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder.
    Varadharajan S; Jumadilova Z; Girase P; Ollendorf DA
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S140-9. PubMed ID: 16161387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder.
    Leung HY; Yip SK; Cheon C; Liu YS; Lau J; Wong HK; Chung KH
    BJU Int; 2002 Sep; 90(4):375-80. PubMed ID: 12175392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.